OTLK
NASD Outlook Therapeutics, Inc.$0.6300 ↑ +0.0043 (+0.69%) Trading Up from the previous close of $0.6257, $0.0059 below the day’s high of $0.6359
- YTD change
- -60.13%
- vs 20-day SMA
- -3.71%
- vs 200-day SMA
- -18.43%
Price ranges
Price & Performance
+0.42 (+209.00%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 99.7% away from all-time highs of $219.2000
- OTLK is down 60% since the beginning of the year
- OTLK is down 41% over the past 12 months
- OTLK is down 2% over the past 1 month
- 14% of all OTLK investors are betting against OTLK
OTLK reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is -41.4%.
- Previous minute
- +$0.0000
- Last hour
- -$0.0004
- Last 5 days
- -8.20%
- vs 8-day SMA
- -4.80%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
